TCGA-CN-A641-01A-11R-A30B-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.590
- MYC_TARGETS_V1+0.480
- E2F_TARGETS+0.400
- PANCREAS_BETA_CELLS+0.380
- G2M_CHECKPOINT+0.290
- UNFOLDED_PROTEIN_RESPONSE+0.290
- MTORC1_SIGNALING+0.160
- ESTROGEN_RESPONSE_LATE+0.150
- SPERMATOGENESIS+0.140
- UV_RESPONSE_UP+0.130
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.530
- INTERFERON_ALPHA_RESPONSE-0.530
- INTERFERON_GAMMA_RESPONSE-0.500
- ALLOGRAFT_REJECTION-0.470
- TGF_BETA_SIGNALING-0.400
- UV_RESPONSE_DN-0.400
- IL2_STAT5_SIGNALING-0.390
- APICAL_SURFACE-0.380
- ANGIOGENESIS-0.360
- IL6_JAK_STAT3_SIGNALING-0.330
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-86-A4D0-01A-11R-A24H-07 | — | cohortA3 | 0.901 |
| 2 | TCGA-39-5037-01A-01R-1443-07 | — | cohortSQ2 | 0.873 |
| 3 | C3L-00965 | — | cohortSQ2 | 0.872 |
| 4 | TCGA-AN-A03Y-01A-21R-A00Z-07 | — | B | 0.864 |
| 5 | SRR8518243 | — | E | 0.858 |
| 6 | SRR4195654 | — | — | 0.857 |
| 7 | TCGA-77-A5G7-01B-11R-A27Q-07 | — | cohortSQ1 | 0.855 |
| 8 | TCGA-66-2754-01A-01R-0980-07 | — | cohortA3 | 0.849 |
| 9 | BS_JZRM1S3T | medulloblastoma | — | 0.847 |
| 10 | C3L-01285 | — | cohortSQ2 | 0.847 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.590 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.480 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.400 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.380 | Cobimetinib | — uncovered |
| G2M_CHECKPOINT | 0.290 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.290 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.160 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.150 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.140 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.130 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.120 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.110 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.080 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.070 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_DN | 0.050 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.020 | Idelalisib | — uncovered |